首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients
【24h】

Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients

机译:螺内酯是安全的,可减少血液透析患者的左室肥大

获取原文
           

摘要

There is recent evidence that aldosterone play a role in the pathogenesis of cardiovascular disease in dialysis patients, which leads to the opportunity to block its actions for the benefit of these patients. In nondialytic chronic kidney disease, spironolactone was safe and effective in reducing left ventricular hypertrophy. However, routine use has been precluded in hemodialysis patients due to the risk of hyperkalemia. The aim of this study is to verify the safety and efficacy in regression of left ventricular hypertrophy with spironolactone in hemodialysis patients undergoing pharmacotherapeutic monitoring.
机译:最近有证据表明,醛固酮在透析患者的心血管疾病的发病机理中起作用,这导致有机会阻止其作用以使这些患者受益。在非透析性慢性肾脏疾病中,螺内酯可以安全有效地减轻左心室肥大。但是,由于存在高钾血症的风险,血液透析患者不能进行常规使用。本研究的目的是验证螺内酯对接受药物治疗监测的血液透析患者左室肥大的安全性和有效性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号